1052 GMT - Merck KGaA's potential acquisition of SpringWorks Therapeutics could boost its cancer-treatment pipeline, but the profitability of the deal is questionable, Equita analyst Davide Marchesin says in a note. "Therapeutics is generating over 350 million euros of annual revenues and it is loss making, therefore one critical question would be if the acquisition would be accretive from year one," the analyst says. The German pharma company's acquisition of the U.S. biopharmaceutical company would be one of the biggest pharma deals for Merck in recent years, potentially amounting to around 4 billion euros with a peak sales potential of over 1.0 billion euros in a few years, he says. Merck's shares are up 0.4% at 135.45 euros. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 11, 2025 05:52 ET (10:52 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。